人人操在线_99影视_亚洲三级片av日日夜夜亲亲摸摸_亚洲人成网亚洲欧洲无码一级毛片_91青青草原网站_含羞草夜夜久无码一区二区_国产综合伦理_2020AV天天日天天射_日日操夜夜操B_又粗又硬免费视频__超碰牛牛精品亚洲_一级毛片特黄免费_欧美日韩亚洲网曝在线_无码毛片网

　　2011年-至今：中國(guó)科學(xué)院上海生命科學(xué)研究院生物化學(xué)與細(xì)胞生物學(xué)研究所，研究員，研究組長(zhǎng)

　　2007-2011年：美國(guó)麻省理工學(xué)院癌癥研究中心，博士后

　　2000-2006年：美國(guó)西北大學(xué)醫(yī)學(xué)院，博士

　　1996-2000年：北京大學(xué)生命科學(xué)學(xué)院，學(xué)士

癌癥是由多種基因突變?cè)斐傻膼盒约膊?。大?guī)模癌癥基因組研究使我們對(duì)癌癥有了更加深入的認(rèn)識(shí)，然而仍有一些關(guān)鍵問(wèn)題亟待解決。一些基因型的腫瘤缺乏可用的治療靶點(diǎn)，此外，許多靶點(diǎn)屬于傳統(tǒng)藥物模式下的“不可成藥”靶點(diǎn)。我們?cè)谝韵聨讉€(gè)方向開(kāi)展研究，以拓展靶向治療。

1) 腫瘤中新治療靶點(diǎn)的發(fā)現(xiàn)。通過(guò)全基因組CRISPR篩選，對(duì)經(jīng)典的癌癥相關(guān)信號(hào)通路如Wnt、TGF、VHL-HIF等進(jìn)行深度研究，發(fā)現(xiàn)這些通路的新的重要調(diào)控基因，其中的一些可為腫瘤提供治療靶點(diǎn)。此外，我們還利用全基因組CRISPR篩選技術(shù)，全面分析決定各類(lèi)藥物抗癌活性的最重要基因。相關(guān)結(jié)論可為各類(lèi)抗癌藥物的精準(zhǔn)使用提供生物標(biāo)志物，也可為這些藥物提供合成致死靶點(diǎn)，從而改善藥物的治療效果。

2) 許多重要疾病的驅(qū)動(dòng)蛋白屬于“難以成藥”靶點(diǎn)，對(duì)應(yīng)了非常大的未滿足患者需求。針對(duì)這類(lèi)靶點(diǎn)的分子膠降解劑是生物醫(yī)學(xué)領(lǐng)域的研究熱點(diǎn)和藥物研發(fā)的重點(diǎn)方向。我們創(chuàng)立了新型高通量降解劑篩選體系，對(duì)各類(lèi)疾病的重要靶點(diǎn)蛋白開(kāi)展降解劑篩選并進(jìn)行后續(xù)研究，為這些“難以成藥”靶點(diǎn)提供新的候選靶向藥物。

1. Chu Y, Chen S, Yang M, Chen Y, Fang H, Huang P, Xie Y, Sun C, Chen Y, Zhang B, Li L, Mu H, Song D, Cheng W, Wang C, Jiang W, Xu X, He Z, Chen S, Liu M, Ma J, Yang M, Cao J, Shen J, Zhang L, Bai Y, Liu Z, Chen J, Dai S, Zeng Y, Zhao Y, Zhou H, Chen C, Ru H, Tan L, Chi X, Wang F, Gao D, Lin M, Deng X* and?Jiang H*.?A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2.?(2025)?Nature Biotechnology? doi: 10.1038/s41587-025-02793-8.?(* Co-corresponding author)
2. Fan P, Shang XY, Song A, Chen S, Mao RY, Ma J, Chen J, Wang Z, Zheng H, Tao B, Hong L, Liu J, XU W, W Jiang, H Shen, Zhang Q, Yang H, Meng XM, Lan F, Cheng J, Xu C, Zhang P*,?Jiang H*,?Chen F*. Catalytic-independent functions of Integrator/INTAC confer sensitivity to BET inhibition. (2025)?Nature Chemical Biology?21(6):959-970.?(* Co-corresponding author)
3. Zhao Y, Jiang W, Gao H, Pan G, Wu Y, Wang Y, Sheng M, Xie J, Wu W, JI Z, Du Y, Zhang L, Wang X, Walsh CP,?Jiang H*,?Xu G*, Zhou D*. DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines. (2023)?Protein & Cell?14(7):532-537. (* Co-corresponding author)
4. He Z, Li R,?Jiang H. Mutations and Copy number abnormalities of hippo pathway components in human cancers. (2021)?Frontiers in Cell and Developmental Biology ?9:661718
5. Xu L, Li P, Hao X, Lu Y, Liu M, Song W, Shan L, Yu J, Ding H, Chen S, Yang A, Zeng YA, Zhang L*,?Jiang H*. SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling. (2021)?Protein & Cell?12(3):174-193. (* Co-corresponding author)
6. Shan L, Yu J, He Z, Chen S, Liu M, Ding H, Xu L, Zhao J, Yang A,?Jiang H. Defining relative mutational difficulty to understand cancer formation. (2020)?Cell Discovery?Jul 21;6:48.
7. Jiang H. The expanding vulnerabilities of being UTXless. (2019)?Signal Transduction and Targeted Therapy.?4:12
8. Ding H, Zhao J, Zhang Y, Yu J, Liu M, Li X, Xu L, Lin M, Liu C, He Z, Chen S,?Jiang H.?Systematic analysis of drug vulnerabilities conferred by tumor suppressor loss. (2019)?Cell Reports?27(11):3331-3344 (Recommended by Faculty of 1000)
9. Li X, Zhang Y, Zheng L, Liu M, Chen CD,?Jiang H. UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma. (2018)?Nature Communications. 9(1):2720.
10. Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y*, Hemann MT*,?Jiang H*. A DNA/HDAC dual-targeting drug with significantly enhanced anticancer potency. (2015)?EMBO Molecular Medicine, 7(4):438-49 (*Co-corresponding author)
11. Wang N, Ding H, Liu H, Li X, Wei L, Yu J, Liu M, Ying M, Gao W,?Jiang H* , Wang Y*. A novel recurrent CHEK2 Y390C mutation identified in high risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk. (2015)?Oncogene, 34(40):5198-205 (*Co-corresponding author)

合影